TG Therapeutics

Yahoo Finance • 3 months ago

TG Therapeutics Inc (TGTX): Short Seller Sentiment is Bearish

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where TG Therapeutics Inc (NASDAQ:TGTX) stands against the other 52-week high stocks. The st... Full story

Yahoo Finance • 11 months ago

TG Therapeutics Reverses Its 225% Winning Streak On Lackluster Guidance

Sales of a new multiple sclerosis drug from TG crushed analysts' expectations, but TGTX stock tumbled on lackluster 2024 guidance. Continue reading... Full story

Yahoo Finance • last year

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Bu... Full story

Yahoo Finance • last year

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 6th Annual Evercore ISI HealthCONx Confer... Full story

Yahoo Finance • last year

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neuro... Full story

Yahoo Finance • last year

Why TG Therapeutics Stock Is Crushing It Today

Shares of the biopharmaceutical company were soaring 36.4% higher as of 11:32 a.m. ET. Why were TG Therapeutics' Q3 results so good? CEO Michael Weiss said in the company's press release announcing its Q3 results that the sales figure for... Full story

Yahoo Finance • last year

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm Approximately 2... Full story

Yahoo Finance • last year

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide... Full story

Yahoo Finance • last year

13 Stocks to Buy with Exponential Growth

In this article, we will take a look at the 13 stocks to buy with exponential growth. To see more such companies, go directly to 5 Stocks to Buy with Exponential Growth. Optimism was prevailing in the US stock market on October 11 as inve... Full story

Yahoo Finance • last year

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of... Full story

Yahoo Finance • last year

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluatin... Full story

Yahoo Finance • last year

15 Best U.S. Stocks to Buy Now Under $10

In this article, we will discuss the 15 best U.S. stocks to buy now under $10. If you want to explore similar stocks, you can also take a look at 5 Best U.S. Stocks to Buy Now Under $10. The U.S. has always been a financial and economic h... Full story

Yahoo Finance • last year

TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

NEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 2023 Cantor Global Healthcare Conference... Full story

Yahoo Finance • 2 years ago

When Will TG Therapeutics, Inc. (NASDAQ:TGTX) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at TG Therapeutics, Inc.'s (NASDAQ:TGTX) future prospects. TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acqu... Full story

Yahoo Finance • 2 years ago

TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Bank of America Securities 2023 Health Car... Full story

Yahoo Finance • 2 years ago

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+ healthcare providers at 125+ centers Payor coverage in place for over 50% of covered lives for BRIUMVI Conference... Full story

Yahoo Finance • 2 years ago

TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 1, 2023, at 8:30 ET to discuss results for the first quarter 2023 and provide a busines... Full story

Yahoo Finance • 2 years ago

TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatmen... Full story

Yahoo Finance • 2 years ago

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing... Full story

Yahoo Finance • 2 years ago

TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recomm... Full story